Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 55853-55854 [2020-19990]

Download as PDF Federal Register / Vol. 85, No. 176 / Thursday, September 10, 2020 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Request for Information (RFI): Testing for Coronavirus Disease 2019 (COVID– 19)—Surge Capacity Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services (HHS). ACTION: Request for information. AGENCY: The Office of the Assistant Secretary for Health (OASH) in the Department of Health and Human Services (HHS) seeks to obtain information regarding the ability of Clinical Laboratory Improvement Amendments (CLIA)-certified/ accredited commercial, academic, medical center, and public health laboratories to feasibly provide additional COVID–19 testing capability if supplementary testing instruments were made available. A set of questions is available in the Supplementary Information section below. DATES: To be considered, comments must be received electronically at the email address provided below, no later than 5:00 p.m. Eastern Time (ET) on September 21, 2020. ADDRESSES: Individuals are encouraged to submit responses electronically to LCDR Natalie Gibson, 200 Independence Avenue SW, Washington, DC 20201, (240) 743–1757, COVID19TestSupplies@hhs.gov. Please indicate ‘‘RFI RESPONSE’’ in the subject line of your email. Submissions received after the deadline will not be reviewed. Responses to this notice are not offers and cannot be accepted by the federal government to form a binding contract or issue a grant. Respond concisely and in plain language. You may use any structure or layout that presents your information well. You may respond to some or all of our questions, and you can suggest other factors or relevant questions. You may also include links to online material or interactive presentations. Clearly mark any proprietary information, and place it in its own section or file. Your response will become government property, and we may publish some of its non-proprietary content. SUPPLEMENTARY INFORMATION: HHS is working together with state, local, tribal and territorial governments, public health officials, health care providers, researchers, private sector organizations, and the public to execute a whole-ofAmerica response to the COVID–19 pandemic to protect the health and safety of the American people. Timely khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:38 Sep 09, 2020 Jkt 250001 and accurate diagnostic testing is paramount to the response. Diagnostic testing must be maximized across all platforms and venues to enable early detection, containment of potential outbreaks, and protect all Americans— especially the vulnerable and otherwise high-risk populations. In order to expand diagnostic testing capacity and fully leverage the national testing ecosystem, the purpose of this request for information (RFI) is to obtain information regarding the ability of CLIA-certified or accredited commercial, academic, medical center and public health laboratories to feasibly provide additional testing capability if supplementary testing instruments and reagents from Thermo Fisher Scientific were made available. Because HHS is seeking to significantly expand testing capability, responses that propose substantial increases in capability, and provide adequate justification (e.g., can demonstrate the necessary personnel, infrastructure and other ancillary support needs to accommodate such expansions) are preferred. We encourage eligible performers to answer the follow questions: • Do you represent a CLIA-certified or accredited laboratory? • What is your current laboratory testing capacity (e.g., installed base of platforms, throughput, level of personnel, etc.)? • What is your current ability to accession specimens and report out laboratory results in no less than 24–48 hours? • What level of additional capacity could your laboratory provide if additional testing instruments were made available? Æ Please provide a proposed request for instruments and any other requirements. Please provide a timeline for implementation of increased capacity, assuming the laboratory receives the requested instruments. This information will inform the ongoing response to the COVID–19 pandemic. Dated: September 3, 2020. Tammy R. Beckham, Director, COVID–19 Laboratory Testing and Diagnostics Working Group. [FR Doc. 2020–19998 Filed 9–9–20; 8:45 am] BILLING CODE 4150–28–P PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 55853 DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Advisory Committee on Blood and Tissue Safety and Availability Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As required by the Federal Advisory Committee Act, the U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a meeting. The meeting will be open to the public. At the August ACBTSA meeting, the committee voted to form work groups to further develop and prioritize actionable recommendations to the Assistant Secretary for Health. For this meeting, the committee will discuss and vote on recommendations from the work groups to improve the blood community’s response to future public health emergencies. SUMMARY: The meeting will take place virtually on Friday, September 25, 2020 from approximately 1:00 p.m.–4:00 p.m. ET. Meeting times are tentative and subject to change. The confirmed times and agenda items for the meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2020-09-25/ index.html when this information becomes available. FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Mary E. Switzer Building, 330 C Street SW, Suite L600, Washington, DC 20024. Email: ACBTSA@hhs.gov; Phone: 202–795–7608. SUPPLEMENTARY INFORMATION: The registration link for the meeting will be posted at https://www.hhs.gov/oidp/ advisory-committee/blood-tissue-safetyavailability/meetings/2020-09-25/ index.html when it becomes available. After registering, you will receive an email confirmation. The public will have an opportunity to present their views to the ACBTSA orally during the meeting’s public comment session or by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to DATES: E:\FR\FM\10SEN1.SGM 10SEN1 55854 Federal Register / Vol. 85, No. 176 / Thursday, September 10, 2020 / Notices provide verbal or written public comment should review instructions at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2020-09-25/ index.html and respond by midnight September 18, 2020 ET. Verbal comments will be limited to three minutes each to accommodate as many speakers as possible. The ACBTSA provides advice to the Secretary through the Assistant Secretary for Health. The Committee advises on a range of policy issues to include: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national survey and data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met regularly since its establishment in 1997. Dated: September 2, 2020. James J. Berger, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2020–19990 Filed 9–9–20; 8:45 am] BILLING CODE 4150–28–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES National Institute on Aging; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. VerDate Sep<11>2014 16:38 Sep 09, 2020 Jkt 250001 Name of Committee: National Institute on Aging Special Emphasis Panel; R24\R25 Diversity in Aging Research. Date: October 6, 2020. Time: 10:00 a.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Carmen Moten, Ph.D., MPH, Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Bldg., 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20814, (301) 402–7703, cmoten@ mail.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; P01 Natives in Alzheimer’s Research. Date: October 13, 2020. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Carmen Moten, Ph.D., MPH, Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Bldg., 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20814, (301) 402–7703, cmoten@ mail.nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; Cardiometabolic Health in Estrogen Cognition Treatment. Date: October 14, 2020. Time: 12:30 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Joshua Jin-Hyouk Park, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (301) 496–6208, joshua.park4@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: September 3, 2020. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–19931 Filed 9–9–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute On Aging; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Rejuvenation mechanisms. Date: October 19, 2020. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Nijaguna Prasad, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Gateway Building, Suite 2W200, Bethesda, MD 20892, (301) 496–9667, nijaguna.prasad@nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; Infrastructure Development. Date: October 26, 2020. Time: 2:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Dario Dieguez, Jr, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (301) 827–3101, dario.dieguez@ nih.gov. Name of Committee: National Institute on Aging Special Emphasis Panel; Fractured Aged Bone Healing and Pain Control. Date: October 28, 2020. Time: 8:30 a.m. to 12:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting). Contact Person: Joshua Jin-Hyouk Park, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building, 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, (301) 496–6208, joshua.park4@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) E:\FR\FM\10SEN1.SGM 10SEN1

Agencies

[Federal Register Volume 85, Number 176 (Thursday, September 10, 2020)]
[Notices]
[Pages 55853-55854]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19990]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Advisory Committee on Blood and Tissue Safety and 
Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As required by the Federal Advisory Committee Act, the U.S. 
Department of Health and Human Services is hereby giving notice that 
the Advisory Committee on Blood and Tissue Safety and Availability 
(ACBTSA) will hold a meeting. The meeting will be open to the public.
    At the August ACBTSA meeting, the committee voted to form work 
groups to further develop and prioritize actionable recommendations to 
the Assistant Secretary for Health. For this meeting, the committee 
will discuss and vote on recommendations from the work groups to 
improve the blood community's response to future public health 
emergencies.

DATES: The meeting will take place virtually on Friday, September 25, 
2020 from approximately 1:00 p.m.-4:00 p.m. ET. Meeting times are 
tentative and subject to change. The confirmed times and agenda items 
for the meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2020-09-25/ when this information becomes available.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Mary E. Switzer Building, 330 C Street SW, 
Suite L600, Washington, DC 20024. Email: [email protected]; Phone: 202-
795-7608.

SUPPLEMENTARY INFORMATION: The registration link for the meeting will 
be posted at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2020-09-25/ when it becomes 
available. After registering, you will receive an email confirmation.
    The public will have an opportunity to present their views to the 
ACBTSA orally during the meeting's public comment session or by 
submitting a written public comment. Comments should be pertinent to 
the meeting discussion. Persons who wish to

[[Page 55854]]

provide verbal or written public comment should review instructions at 
https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2020-09-25/ and respond by midnight 
September 18, 2020 ET. Verbal comments will be limited to three minutes 
each to accommodate as many speakers as possible.
    The ACBTSA provides advice to the Secretary through the Assistant 
Secretary for Health. The Committee advises on a range of policy issues 
to include: (1) Identification of public health issues through 
surveillance of blood and tissue safety issues with national survey and 
data tools; (2) identification of public health issues that affect 
availability of blood, blood products, and tissues; (3) broad public 
health, ethical, and legal issues related to the safety of blood, blood 
products, and tissues; (4) the impact of various economic factors 
(e.g., product cost and supply) on safety and availability of blood, 
blood products, and tissues; (5) risk communications related to blood 
transfusion and tissue transplantation; and (6) identification of 
infectious disease transmission issues for blood, organs, blood stem 
cells and tissues. The Committee has met regularly since its 
establishment in 1997.

    Dated: September 2, 2020.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue 
Safety and Availability, Office of Infectious Disease and HIV/AIDS 
Policy.
[FR Doc. 2020-19990 Filed 9-9-20; 8:45 am]
BILLING CODE 4150-28-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.